Left Bundle Branch Area Pacing (LBBAP)
ProcedureLeft bundle branch area pacing using conventional stylet driven pacemaker leads for cardiac resynchronization therapy
NCT Number: NCT05365568
The aim of this study proposal is to compare the effectiveness of two distinct pacing modalities for cardiac resynchronization therapy. Our primary hypothesis is that left bundle branch area pacing (LBBAP) using conventional stylet driven pacemaker leads is an effective resynchronization method that yield to at least similar clinical benefits and outcomes when compare to biventricular pacing.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Interventional
Not applicable
UZA, Edegem, Antwerpen, Belgium
Recently some retrospective or uncontrolled studies were published that compared cardiac resynchronization therapy (CRT) using left bundle branch area pacing (LBBAP) and biventricular pacing (BiV), although with a limited number of patients. Moreover, only one of these studies compared LBBAP + right ventricle stimulation to conventional BiV stimulation prospectively. None of the studies used conventional stylet-driven pacemaker leads for LBBAP. Therefore, the present trial aims to fill-in the gap in the current literature regarding LBBAP for CRT and provide a first randomized head-to-head comparison against CRT.
The aim of this study proposal is to compare the effectiveness of two distinct pacing modalities for cardiac resynchronization therapy. Our primary hypothesis is that left bundle branch area pacing (LBBAP) using conventional stylet driven pacemaker leads is an effective resynchronization method that yields to at least similar clinical benefits and outcomes when compared to biventricular pacing.
The study is a multicentre, randomized trial comparing LBBAP against biventricular pacing. After characterization of the type device implanted (Pacing or Defibrillator), randomization will occur between both groups in a 1:1 ratio. The trial purpose is to demonstrate the efficacy of LBBAP to treat clinical heart failure in-patient indicated to receive a CRT.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Left bundle branch area pacing using conventional stylet driven pacemaker leads for cardiac resynchronization therapy
Cardiac resynchronization therapy (CRT) using biventricular pacing (BiV)
Time frame: 12 months
First occurrence of one of the following clinical events: death, hospitalization or unscheduled visit for heart failure (HF) or worsening HF symptoms with adaptation of the medical therapy, implant failure for any cause, implantable electronic cardiac device (IECD) re-intervention for any reason during follow-up (Lead Dislocation/phrenic nerve stimulation…)
Time frame: 1 day
Improvement of procedural characteristics: Operative and fluoroscopic times
Time frame: 1/6/12 months
Correction of electrical desynchrony post-implant, at 1/6/12 months
Time frame: 6 months
Clinical functional response as evaluated by the improvement of the 6 Minutes Walk Test (6MWT) at 6 months follow-up
Time frame: 6/12 months
Left ventricular reverse remodelling at 6 and 12 months follow-up as evaluated by the reduction of the Left Ventricular End-systolic Volume (LVESV) using trans-thoracal echocardiography
Time frame: 6/12 months
ICD therapies at 6 and 12 months
AZ Sint-Jan AV
Other
Left Bundle Branch Area Pacing Using Conventional Stylet Driven Pacemaker Leads for Cardiac Resynchronization Therapy: a Randomized Study
Acronym: LeCaRT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05824923
Cardiovascular Diseases, Heart Diseases
Shenyang, Liaoning, China
View Trial DetailsNCT05774509
Heart Failure With Reduced Ejection Fraction
Paris, France
View Trial DetailsNCT05855135
Arrhythmias, Cardiac, CCM Therapy
Glendale, Arizona, United States
View Trial DetailsNCT06859970
Ambulatory Heart Failure, NYHA Class IV, Cardiovascular Diseases
Jonesboro, Arkansas, United States
View Trial Details